A new study finds Black Medicare beneficiaries with early-stage non–small cell lung cancer (NSCLC) continues to receive curative treatment at lower rates than White patients, highlighting ongoing ...

In the absence of trials, a post hoc analysis compared stereotactic body radiotherapy (SBRT) and high-dose-rate brachytherapy (HDR-BT) in intermediate-risk prostate cancer.

Patients in their 80s and 90s who have early stage lung cancer but cannot undergo an operation can be treated safely and effectively with stereotactic body radiation therapy (SBRT), according to ...

The findings, published in JAMA Network Open, were reported by Cristian Udovicich of the Odette Cancer Centre at Sunnybrook Health Sciences Centre, Toronto, Canada, and colleagues. The investigators ...

In oligometastatic castration-resistant prostate cancer, the rationale to use local SBRT is improved disease control.

Intent-to-treat median PFS was 10.2 months with nivolumab/ipilimumab versus 6.3 months with added SBRT, with 12-month PFS 47.8% versus 34.9% (HR 1.20; P=.56). Per-protocol analysis after four ...

Recent results from the Phase III NRG-RTOG 1112 clinical study showed that the addition of stereotactic body radiotherapy (SBRT) to systemic therapy with sorafenib significantly improved ...

SBRT reduced biochemical failure and acute GU toxicity compared with HDR brachytherapy in intermediate-risk prostate cancer. Read more about the findings.

Minimally invasive surgery (MIS) and stereotactic body radiotherapy (SBRT) are both used to treat stage 1 non-small cell lung cancer (NSCLC). While MIS remains the standard of care for patients with ...

Recent results from the Phase III NRG-RTOG 1112 clinical study showed that the addition of stereotactic body radiotherapy (SBRT) to systemic therapy with sorafenib significantly improved ...

Medical Team's Use of Accuray CyberComm™ Reduced Commissioning Time by Approximately 50 Percent*, Enabling Them to Initiate Patient Treatments Sooner The CyberKnife System facilitates ...